HK Stock Market Move | XINTE ENERGY (01799) rose more than 8% in the morning session, and the production of polycrystalline silicon in April may be lower than previously expected.
Xin Tian Energy (01799) rose over 8% in the early trading session, as of the time of writing, it is up 7.12% to HK$5.72, with a trading volume of HK$101.59 million.
XINTE ENERGY (01799) rose more than 8% in the morning session, up 7.12% at the time of publication, at HK$5.72, with a turnover of HK$101.159 million.
On the news front, according to Shanghai Nonferrous Network, some domestic polysilicon restarts in April have been delayed or undergoing maintenance, resulting in potential lower production than previously expected, with an estimated production of less than 90,000 tons in the domestic market in April. While there has been an increase in previous market orders, there is still pressure from excessive inventory in the polysilicon market compared to supply.
It is worth noting that the Central Committee and State Council have recently issued opinions on promoting the deepening of reforms in industry associations and chambers of commerce, clearly stating the need for strict management of the establishment of enterprises within these associations. In January this year, the Market Regulation Administration required the China Photovoltaic Industry Association and the companies it spoke with to not agree on production capacity, utilization rates, production and sales volumes, or sales prices; not to divide the market, distribute production capacity, or distribute profits in any form; and not to communicate or coordinate on pricing, costs, production and sales volumes, and other information both currently and in the future.
Related Articles

The revolution of subcutaneous vein transfer has arrived, KJ017 has officially been approved, Boji Pharmaceutical (02659) is becoming the "hub core" of the large molecule drug ecosystem.

PACIFIC LEGEND (08547): 49.5% of the stock offering has received valid applications and acceptance.

SHOUCHENG (00697) invests in Zhihang Shi to promote the development of China's intelligent manufacturing industry on the global stage.
The revolution of subcutaneous vein transfer has arrived, KJ017 has officially been approved, Boji Pharmaceutical (02659) is becoming the "hub core" of the large molecule drug ecosystem.

PACIFIC LEGEND (08547): 49.5% of the stock offering has received valid applications and acceptance.

SHOUCHENG (00697) invests in Zhihang Shi to promote the development of China's intelligent manufacturing industry on the global stage.

RECOMMEND

400 Companies Queue For Hong Kong IPOs As Q1 Fundraising Tops Global Rankings
16/04/2026

Why The Hang Seng Is Under Pressure While The AI Sector Trades Independently? Three Core Hong Kong AI Assets To Watch
16/04/2026

Holiday Effect Spurs Short‑Term Uptick In Hong Kong Consumer Stocks As Policy Supports Travel Spending
16/04/2026


